Table 2.
Clinical scenarios | Rationale for dexmedetomidine use | Appropriate | Inappropriate | Uncertain |
---|---|---|---|---|
Medical patients | ||||
Weaning from sedation in patients with prolonged mechanical ventilation (>72 h) | DEX does not impair respiratory drive | 17 | 0 | 0 |
DEX improves the comfort and interaction with the environment | 17 | 0 | 0 | |
Underlying degenerative cerebral diseases | DEX reduces the occurrence of delirium and exerts protective effects on cognitive function | 17 | 0 | 0 |
Weaning from sedation in patients with substance abuse | DEX reduces neurovegetative response to stress | 15 | 0 | 2 |
Patients undergoing NIV | ||||
Dose-dependent respiratory drive depression induced by current sedatives | DEX does not impair respiratory drive | 17 | 0 | 0 |
Airway control in sedated patients undergoing NIV | DEX allows better upper airway protection and reduces the occurrence of bronchoconstriction | 17 | 0 | 0 |
Risk of oversedation and difficulties in obtaining a light sedation level | DEX pharmacodynamics reduces the risk of oversedation | 14 | 0 | 3 |
Sleep disturbances | DEX improves sleep quality, mimicking natural electroencephalography pattern | 16 | 0 | 1 |
Intolerance to NIV in patients with agitation/delirium | DEX improves the comfort and interaction with the environment | 17 | 0 | 0 |
Patients with post-cardiac surgery | ||||
Dose-dependent respiratory drive depression induced by current sedatives | DEX does not impair respiratory drive | 17 | 0 | 0 |
Propofol and benzodiazepines show no analgesia properties | DEX may exert synergic analgesia effects | 16 | 0 | 0 |
Gastrointestinal paralysis due to opioid use | DEX may reduce the occurrence of gastrointestinal paralysis due to opioid use | 13 | 0 | 3 |
Patients with delirium | ||||
Risk of oversedation and difficulties in obtaining a light sedation level | DEX does not impair respiratory drive | 17 | 0 | 0 |
DEX improves the comfort and interaction with the environment | 15 | 0 | 2 | |
Use of benzodiazepines may increase the incidence of delirium | DEX reduces the occurrence of delirium and exerts protective effects on cognitive function | 17 | 0 | 0 |
Practical use of antipsychotics and anxiolytics for agitation and delirium | DEX in combination with antipsychotics preserves cognitive function and reduces the occurrence of delirium | 15 | 0 | 2 |
DEX allows reduction of other antipsychotics | 14 | 1 | 2 |
DEX: dexmedetomidine; NIV: non invasive ventilation